Orexigen Therapeutics, Inc., the maker of the weight loss drug, Contrave, said recently it is withdrawing its efforts for U.S. approval, following the FDA’s refusal to approve its product for use. Contrave was considered to be one of the most promising drug candidates currently in development for the treatment of obesity.

Orexigen released a statement last week in which the company says it will focus on developing Contrave and another drug, Empatic, in non-U.S. markets, as the drugs’ outlook is currently dim in the United States.

The FDA said it would not approve the drug due to concerns over its side effects on the heart. To that end, the FDA plans to hold an advisory committee meeting on cardiovascular risk assessment for obesity drugs sometime in 2012.

RESULTS & SETTLEMENTS

Frank M. Eidson P.A. has been tirelessly representing the rights of Central Florida victims since 1989.

$4.2 Million

Auto Accident

$2.3 Million

Workers Comp Case

$5.65 Million

Auto Accident

LEARN MORE

Free, No Obligation Case Review.

Fill out our contact form below for your free, no obligation case review.

  • This field is for validation purposes and should be left unchanged.
Help provide wounded servicemen and women with therapeutic outdoor adventures. Like our Facebook page and we'll contribute $1 to Wounded Warriors Outdoors.

Contact Our Orlando Attorney

If you have been injured in an accident, turn to Frank M. Eidson P.A. Whether your case is a simple collision or a complicated auto wrongful death case, contact personal injury lawyer Frank Eidson today to schedule your free consultation.

407-245-2887